Pfizer wins more docs in preliminary discovery saga over Enbrel biosimilar

Ashurst 2021-11-18 12:46 pm By Christine Caulfield | Melbourne

Please login to bookmark

Five years into a preliminary discovery application for a potential patent infringement lawsuit over a biosimilar of its Enbrel medication, Pfizer has partially succeeded in obtaining further documents from Samsung Bioepis.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au